GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Turmeric Acquisition Corp (NAS:TMPMU) » Definitions » Preferred Stock

Turmeric Acquisition (Turmeric Acquisition) Preferred Stock : $0.00 Mil (As of Jun. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Turmeric Acquisition Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. Turmeric Acquisition's preferred stock for the quarter that ended in Jun. 2022 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Turmeric Acquisition's Enterprise Value for the quarter that ended in Jun. 2022 was $-0.02 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Turmeric Acquisition's Book Value per Share for the quarter that ended in Jun. 2022 was $.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Turmeric Acquisition's Earnings per Share (Diluted) for the three months ended in Jun. 2022 was $.


Turmeric Acquisition Preferred Stock Historical Data

The historical data trend for Turmeric Acquisition's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turmeric Acquisition Preferred Stock Chart

Turmeric Acquisition Annual Data
Trend Dec20 Dec21
Preferred Stock
- -

Turmeric Acquisition Quarterly Data
Aug20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Preferred Stock Get a 7-Day Free Trial - - - - -

Turmeric Acquisition Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


Turmeric Acquisition  (NAS:TMPMU) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Turmeric Acquisition's Enterprise Value for the quarter that ended in Jun. 2022 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Turmeric Acquisition's Book Value per Share for the quarter that ended in Jun. 2022 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Turmeric Acquisition's Earnings per Share (Diluted) (EPS) for the three months ended in Jun. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Turmeric Acquisition Preferred Stock Related Terms

Thank you for viewing the detailed overview of Turmeric Acquisition's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Turmeric Acquisition (Turmeric Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
450 Kendall Street, Cambridge, MA, USA, 02142
Turmeric Acquisition Corp is a blank check company.
Executives
Luke Evnin officer: Chief Executive Officer THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Mitchell H. Finer director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Edward Hurwitz officer: Chief Financial Officer
Todd Foley officer: President THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Pablo J Cagnoni director ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080
David P Meeker director C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Andrew R Robbins director C/O 3200 WALNUT ST, BOULDER CO 80301
Matthew Roden director 450 KENDALL STREET, CAMBRIDGE MA 02142
Turmeric Management, Llc 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Vinay Bhaskar officer: Chief Operating Officer 2000 SIERRA POINT PARKWAY, SUITE 701, BRISBANE CA 94005